Rallybio Stock Soars After $50M Merger Termination Fee

Merger Collapse Yields Windfall

Rallybio Corporation's stock, trading under NASDAQ:RLYB, experienced a dramatic surge of 47.4% on Monday. This followed the announcement that the company will receive a $50 million parent termination fee after its planned merger with Candid Therapeutics, Inc. was canceled.

Overview of the Situation

Candid Therapeutics officially terminated the Merger Agreement on May 3, 2026, as it entered into an alternative agreement with UCB S.A. The original merger terms, established on March 1, 2026, entitled Rallybio to the termination fee. Both parties have entered a waiver to facilitate the payment and release all related claims.

Impact on the Market

The receipt of the $50 million fee represents a significant non-dilutive capital infusion for Rallybio, strengthening its financial position. The market's positive reaction, reflected in the stock price jump, indicates investor confidence in the company's improved cash runway and future strategic flexibility. Rallybio now plans to withdraw its related Form S-4 registration statement from the SEC.

Summary

The substantial termination fee provides Rallybio with a considerable financial boost, removing merger-related uncertainties. Investor focus will now likely shift to how the company utilizes this capital to advance its clinical development pipeline and enhance shareholder value.

FAQ

Q: Why did Rallybio's stock price increase so much?
A: The stock surged 47.4% after the company announced it would receive a $50 million termination fee from a canceled merger.

Q: Who terminated the merger agreement with Rallybio?
A: Candid Therapeutics, Inc. terminated the agreement to pursue an alternative deal with UCB S.A.

Source: Investing.com